Cryoport Q2 FY26 net loss narrows to $8.3 million; revenue rises 8% to $49 million year-over-year
CYRX•Quarterly results
Cryoport Q2 revenue rose 8% year over year to USD 49 million; loss attributable to common stockholders was USD 10.3 million, or USD 0.20 per share.
Loss from continuing operations narrowed to USD 8.3 million from a year-earlier loss; net loss was USD 8.3 million versus prior-year net income.
Profitability and margins
Adjusted EBITDA from continuing operations (non-GAAP) swung to a profit of USD 0.4 million from a year-earlier loss; gross margin slipped 0.4 percentage points to 46.6%.
Business segment performance
Life Sciences Services revenue climbed 15% to USD 28 million, led by 25% growth in BioStorage/BioServices to USD 5.6 million.
Clinical and commercial activity
Supported 779 clinical trials and 22 commercial cell and gene therapies as of June 30, 2026; management cited a “pathway to profitability” milestone on positive adjusted EBITDA.
